Modeling the Binding and Conformational Energetics of a Targeted Covalent Inhibitor to Bruton's Tyrosine Kinase

被引:21
|
作者
Awoonor-Williams, Ernest [1 ,2 ]
Rowley, Christopher N. [3 ]
机构
[1] Mem Univ Newfoundland, Dept Chem, St John, NF A1B 3X9, Canada
[2] Novartis Inst BioMed Res, 181 Massachusetts Ave, Cambridge, MA 02139 USA
[3] Carleton Univ, Dept Chem, Ottawa, ON K1S 5B6, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
FREE-ENERGY CALCULATIONS; PROTEIN-KINASES; DRUG DISCOVERY; SIDE-CHAINS; GLEEVEC; SELECTIVITY; MODIFIERS; POTENCY; DESIGN; ABL;
D O I
10.1021/acs.jcim.1c00897
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Targeted covalent inhibitors (TCIs) bind to their targets in both covalent and noncovalent modes, providing exceptionally high affinity and selectivity. These inhibitors have been effectively employed as inhibitors of protein kinases, with Taunton and coworkers (Nat. Chem. Biol. 2015, 11, 525-531) reporting a notable example of a TCI with a cyanoacrylamide warhead that forms a covalent thioether linkage to an active-site cysteine (Cys481) of Bruton's tyrosine kinase (BTK). The specific mechanism of the binding and the relative importance of the covalent and noncovalent interactions is difficult to determine experimentally, and established simulation methods for calculating the absolute binding affinity of an inhibitor cannot describe the covalent bond-forming steps. Here, an integrated approach using alchemical free-energy perturbation and QM/MM molecular dynamics methods was employed to model the complete Gibbs energy profile for the covalent inhibition of BTK by a cyanoacrylamide TCI. These calculations provide a rigorous and complete absolute Gibbs energy profile of the covalent modification binding process. Following a classic thiol-Michael addition mechanism, the target cysteine is deprotonated to form a nucleophilic thiolate, which then undergoes a facile conjugate addition to the electrophilic functional group to form a bond with the noncovalently bound ligand. This model predicts that the formation of the covalent linkage is highly exergonic relative to the noncovalent binding alone. Nevertheless, noncovalent interactions between the ligand and individual amino acid residues in the binding pocket of the enzyme are also essential for ligand binding, particularly van der Waals dispersion forces, which have a larger contribution to the binding energy than the covalent component in absolute terms. This model also shows that the mechanism of covalent modification of a protein occurs through a complex series of steps and that entropy, conformational flexibility, noncovalent interactions, and the formation of covalent linkage are all significant factors in the ultimate binding affinity of a covalent drug to its target.
引用
收藏
页码:5234 / 5242
页数:9
相关论文
共 50 条
  • [41] A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers
    Smith, Patrick F.
    Krishnarajah, Janakan
    Nunn, Philip A.
    Hill, Ron J.
    Karr, Dane
    Tam, D.
    Masjedizadeh, Mohammad
    Funk, Jens O.
    Gourlay, Steve G.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 83 (11) : 2367 - 2376
  • [42] Raynaud's phenomenon as an adverse event associated with Bruton tyrosine kinase inhibitor
    Deligeorgakis, Dimitrios
    Adamichou, Christina
    RHEUMATOLOGY, 2024, 63 (08) : e222 - e223
  • [43] Stability and binding of SH3 domain of Bruton's tyrosine kinase
    Cheng, JW
    Patel, HV
    Tzeng, SR
    Liao, CY
    PEPTIDES: FRONTIERS OF PEPTIDES SCIENCE, 1999, : 565 - 566
  • [44] Identification of the binding site for Gqα on its effector Bruton's tyrosine kinase
    Ma, YC
    Huang, XY
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (21) : 12197 - 12201
  • [45] Non-Covalent Bruton's Tyrosine Kinase Inhibitors in the Treatment of Chronic Lymphocytic Leukemia
    Montoya, Skye
    Thompson, Meghan C. C.
    CANCERS, 2023, 15 (14)
  • [46] Covalent Bruton tyrosine kinase inhibitors across generations: A focus on zanubrutinib
    Broccoli, Alessandro
    Del Re, Marzia
    Danesi, Romano
    Zinzani, Pier Luigi
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2025, 29 (03)
  • [47] Design of Potent and Selective Covalent Inhibitors of Bruton's Tyrosine Kinase Targeting an Inactive Conformation
    Pulz, Robert
    Angst, Daniela
    Dawson, Janet
    Gessier, Francois
    Gutmann, Sascha
    Hersperger, Rene
    Hinniger, Alexandra
    Janser, Philipp
    Koch, Guido
    Revesz, Laszlo
    Vulpetti, Anna
    Waelchli, Rudolf
    Zimmerlin, Alfred
    Cenni, Bruno
    ACS MEDICINAL CHEMISTRY LETTERS, 2019, 10 (10): : 1467 - 1472
  • [48] Bruton's Tyrosine Kinase in Ankylosing Spondylitis
    Liao, Hsien-Tzung
    Chen, Chun-Hsiung
    SPINE, 2024, 49 (10) : 677 - 681
  • [49] Bruton's tyrosine kinase: oncotarget in myeloma
    Tai, Yu-Tzu
    Anderson, Kenneth C.
    ONCOTARGET, 2012, 3 (09) : 913 - 914
  • [50] Targeting Bruton's Tyrosine Kinase in CLL
    Ahn, Inhye E.
    Brown, Jennifer R.
    FRONTIERS IN IMMUNOLOGY, 2021, 12